No abstract

Background Exercise may improve clinical and quality of life outcomes for men with prostate cancer. No randomized controlled trials (RCTs) have examined the feasibility, safety, and acceptability of remote exercise training in men with metastatic castrate‐resistant prostate cancer (mCRPC). Methods We conducted a pilot RCT (1:1:1 aerobic or resistance exercise 3x/week or usual care) to determine the feasibility, safety, and acceptability of remotely monitored exercise over 12 weeks in 25 men with mCRPC. A prescribed exercise program was based on baseline testing including high‐ and moderate‐intensity aerobic exercise or resistance exercise completed at a local exercise facility. Feasibility was based on attendance, adherence, and tolerance; safety on adverse events; and acceptability on participant interviews. Results Between March 2016 and March 2020, 25 patients were randomized (8 aerobic, 7 resistance, and 10 control). Twenty‐three men (82%) completed the 12‐week study. Men who completed the remote intervention attempted 90% and 96% of prescribed aerobic and resistance training sessions, respectively, and 86% and 88% of attempted sessions were completed as or more than prescribed. We observed changes in performance tests that corresponded with the exercise prescription. No safety concerns were identified. Ninety percent of participants interviewed were satisfied with the program and would recommend it to others. Conclusions Remotely monitored exercise training is feasible, safe, and acceptable in men with mCRPC; there was no difference in these outcomes by mode of exercise. Through this research, we provide direction and rationale for future studies of exercise and clinical outcomes in patients with metastatic prostate cancer.

Background Cutaneous metastases (CM) diagnosis is clinically challenging, requiring an invasive biopsy for confirmation. A novel, RCM‐OCT device combines the advantage of horizontal high‐resolution reflectance confocal microscopy (RCM) images and vertical deeper optical coherence tomography (OCT) images to aid in non‐invasive diagnosis of CM from breast cancers. Objective Characterize CM from breast cancers using RCM‐OCT device. Methods Seven patients suffering from breast cancers with suspicious CM were consented and imaged with RCM‐OCT device. CM features were defined by comparing with histopathology. Tumour depths were measured on OCT and on H&E‐images and correlated using statistical analysis Pearson test. 3D‐OCT images were reconstructed to enhance tumour visualization. Results 6/7 lesions were CM from breast cancers, and one was vascular ectasia, on histopathology. CM appeared as greyish‐darkish oval to round structures within the dermis on RCM and OCT‐images. On RCM, individual tumour cells were seen, enabling identification of even small tumour foci; while, on OCT deeper tumours were detected. Inflammatory cells, dilated vessels and coarse collagen were identified in the dermis. Pearson correlation had an r2 of 0.38 and a significant P‐value <0.004 for depth measurements. CM from breast cancers could be differentiated from ecstatic vessels on 3D‐reconstructed OCT image. Limitation Small sample size and lack of clinical mimickers. Conclusion RCM‐OCT can detect CM and has potential in aiding non‐invasive diagnosis and management.